Sensitivity to Intravenous Nicotine: Genetic Moderators


Influence of OPRM1 A118G Status on Subjective Responses to IV Nicotine.

What is the purpose of this trial?

To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV nicotine when compared to those with AA genotype.

Participation Guidelines

18 Years - 50 Years

Click here for detailed information about who can participate in this trial.

National Institute on Drug Abuse (NIDA)
Yale University
June 2009
Last Updated:
June 13, 2014
Study HIC#: ID: NCT00969137